ArticleEmergency medicine international2024
Clinical Features and Biomarkers for Early Prediction of Refractory Mycoplasma Pneumoniae Pneumonia in Children.
Article in Emergency medicine international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.
- Prevalence, risk factors, and early prediction of refractory pneumonia caused by Mycoplasma pneumoniae in children: a systematic review and meta-analysis.European journal of pediatrics · 2026Pooled it
- Risk factors for refractoryFrontiers in pediatrics · 2025Pooled it
- Development and validation of a multivariate predictive model for the risk of refractory mycoplasma pneumoniae pneumonia in children based on quantitative computed tomography features.Translational pediatrics · 2026Article
- Association between normalizedTranslational pediatrics · 2026Article
- A retrospective clinical risk prediction model for co‑infection with Mycoplasma pneumoniae in patients with COVID‑19 based on restricted cubic splines.Scientific reports · 2026Article
- A nursing perspective on bronchoscopic intervention strategies for children with macrolide-unresponsiveFrontiers in medicine · 2026Article
- Dynamic multiplex cytokine profiling to identify risk factors for Lung Consolidation and Necrotizing Transformation in Children withMediterranean journal of hematology and infectious diseases · 2026Article
- Influence of Mycoplasma Resistance Genes on Pediatric Mycoplasma Pneumonia Treatment and Determinants for Second-line Antimicrobial Adjustment.Combinatorial chemistry & high throughput screening · 2026Article
- AgeFrontiers in pediatrics · 2026Article
- Association Between Pre-Admission 48-Hour Fever Burden and Outcomes in Pediatric Mycoplasma Pneumoniae Infection.Mediterranean journal of hematology and infectious diseases · 2026Article
- A fever-based therapeutic window for bronchoscopy to prevent bronchiolitis obliterans in children with Mycoplasma pneumoniae pneumonia.Frontiers in pediatrics · 2026Article
- Comparison of Different Corticosteroid Regimens for RefractoryInfection and drug resistance · 2026Article
- Prediction models for refractoryFrontiers in pediatrics · 2026Article
- The impact of the COVID-19 pandemic on the epidemiology, clinical manifestations and molecular characteristics ofFrontiers in immunology · 2026Review
- Highly sensitive PfAgo-based biosensor for the detection of mutations in the 23S rRNA gene of macrolide-resistant Mycoplasma pneumoniae.Analytical and bioanalytical chemistry · 2025Article
- Establishment and validation of a predictive model for Lobar pneumonia caused by Mycoplasma pneumoniae infection in children.Scientific reports · 2025Article
- Article
- Efficacy analysis of ultrashort wave therapy as adjunctive treatment for pediatric patients with macrolide-resistant Mycoplasma pneumoniae pneumonia.Frontiers in cellular and infection microbiology · 2025Article
- Biomarkers associated with the diagnosis and prognosis ofFrontiers in cellular and infection microbiology · 2025Review
- Serum inflammatory markers in children withWorld journal of clinical cases · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The study aimed to analyze the clinical characteristics of children with RMPP and to explore the biomarkers for the early prediction of RMPP, thus providing references for the clinical diagnosis and treatment of RMPP in children. Methods: Baseline clinical characteristics, clinical symptoms, physical examination, chest imaging, and laboratory indicators between children with RMPP and general refractory mycoplasma pneumoniae pneumonia (GMPP) were compared. Multiple logistic regression analysis was used to determine independent risk factors for RMPP. ROC curves were adopted to analyze the predictive values of biomarkers. Results: The RMPP group had more severe clinical symptoms and manifestations on imaging (including pleural effusion, pulmonary consolidation, and pulmonary atelectasis), a higher incidence of extrapulmonary complications, and a longer duration of hospital stays. Results of multiple logistic regression analysis showed that serum D-dimer (OR = 8.169, Conclusions: Serum D-dimer, CRP, and LDH levels were related to the severity of mycoplasma pneumoniae pneumonia in children and had potential as biomarkers for the early prediction of RMPP, suggesting great applicative values for the early diagnosis and timely intervention of children with RMPP in clinical practice.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.